COMMUNIQUÉS West-GlobeNewswire

Essilor - Communiqué : Mise à disposition du rapport financier semestriel 2018
26/07/2018
Mise à disposition du rapport financier semestriel 2018 Version PDF du communiqué Charenton-le-Pont, France (le 26 juillet 2018 - 06h30) - Essilor International (Compagnie Générale d'Optique) publie ce matin son rapport [...]
REVA Enters Peripheral Artery Disease Space With First-Ever CE Mark of a Bioresorbale Scaffold for Below the Knee Therapy
26/07/2018
SAN DIEGO, July 25, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, today announced that its MOTIV™ [...]
Telix Pharmaceuticals and JFE Progress Japanese Manufacturing Partnership
26/07/2018
MELBOURNE, Australia and TOKYO, July 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“ Telix ”, the “ Company ”), an Australian biopharmaceutical company focused on the development of diagnostic [...]
R1 RCM to Release Second Quarter 2018 Results on August 9
26/07/2018
CHICAGO, July 25, 2018 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-enabled revenue cycle management (RCM) services to healthcare providers, today announced it expects to release [...]
Merit Medical Announces Pricing of Public Offering of Common Stock
26/07/2018
SOUTH JORDAN, Utah, July 25, 2018 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) (“ Merit ”), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and [...]
BioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine
26/07/2018
73.8% reduction in attacks with significant benefits in quality of life from once-daily oral dosing of BCX7353 125 mg RESEARCH TRIANGLE PARK, N.C., July 25, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. ( [...]
New Phase 2 Data Analysis for Crenezumab Presented at Global Alzheimer's Conference Provides Strong Evidence for Engagement of the Principle Abeta Target
25/07/2018
Crenezumab significantly reduces Abeta oligomers in cerebrospinal fluid (CSF) in patients with Alzheimer's disease Strong evidence for principal target engagement of Abeta oligomers, the most neurotoxic species of the [...]
MPX Provides Additional and Updated Disclosures in Revised Management’s Discussion and Analysis
25/07/2018
TORONTO, July 25, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“ MPX ” or the “ Company ”) (CSE:MPX) (OTC:MPXEF) announced that it has filed today a Revised and Restated Management’s Discussion and Analysis ( [...]
Golden Leaf Holdings Receives State Licensure Approval For Extraction Facility In Portland
25/07/2018
PORTLAND, Ore., July 25, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“GLH” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a cannabis company with cultivation, production and retail operations built around recognized [...]
Helix BioPharma Corp. Completes Fourth Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47
25/07/2018
RICHMOND HILL, Ontario, July 25, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and [...]
Myriad Announces Publication of IMPACT Study in Journal of Psychiatric Research
25/07/2018
Results Show that Primary Care Physicians Obtained Improved Outcomes for Patients with Depression When Medication Selection Is Guided by the GeneSight® Test SALT LAKE CITY, July 25, 2018 (GLOBE NEWSWIRE) -- Myriad [...]
Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial Placed on Clinical Hold Due to an Out-of-Specification Production Lot; No Observed Safety Events
25/07/2018
-- Out-of-specification lot resulted from the presence of trace levels of DNA fragment in research-grade raw material plasmid sourced from third-party manufacturer -- -- Fragment fully characterized; preliminary testing [...]
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
25/07/2018
TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: [...]
Savara Announces Proposed Public Offering of Common Stock
25/07/2018
AUSTIN, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq:SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in [...]
Histogenics Corporation to Present at Canaccord Genuity’s 38th Annual Growth Conference
25/07/2018
WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored [...]
The Cooper Companies Announces Release Date for Third Quarter 2018
25/07/2018
PLEASANTON, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced it will release third quarter 2018 financial results on Thursday, August 30, 2018, at 4:15 PM ET. Following the [...]
Supernus to Host Second Quarter 2018 Earnings Conference Call
25/07/2018
ROCKVILLE, Md., July 25, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]
BioTelemetry, Inc. Reports Second Quarter 2018 Financial Results
25/07/2018
Company Delivers Record Results Raises Full-Year Guidance MALVERN, Pa., July 25, 2018 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote and wireless medical technology company focused on the [...]
EyePoint Pharmaceuticals Announces Presentation of Data Highlighting YUTIQ™ for Posterior Segment Uveitis at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
25/07/2018
YUTIQ ™ delivers positive twelve month efficacy vs sham with reduced rates of recurrence and reduced use of rescue therapies in patients with noninfectious posterior segment uveitis NDA currently under review by FDA; [...]

Pages